Abstract
Multiple myeloma (MM), a malignant tumor of somatically mutated, isotype-switched plasma cells (PC), usually arises from a common benign PC tumor called Monoclonal Gammopathy of Undetermined Significance (MGUS). MM progresses within the bone marrow, and then to an extramedullary stage from which MM cell lines are generated. The incidence of IgH translocations increases with the stage of disease: 50% in MGUS, 60–65% in intramedullarly MM, 70–80% in extramedullary MM, and >90% in MM cell lines. Primary, simple reciprocal IgH translocations, which are present in both MGUS and MM, involve many partners and provide an early immortalizing event. Four chromosomal partners appear to account for the majority of primary IgH translocations: 11q13 (cyclin D1), 6p21 (cyclin D3), 4p16 (FGFR3 and MMSET), and 16q23 (c-maf). They are mediated primarily by errors in IgH switch recombination and less often by errors in somatic hypermutation, with the former dissociating the intronic and 3′ enhancer(s), so that potential oncogenes can be dysregulated on each derivative chromosome (e.g., FGFR3 on der14 and MMSET on der4). Secondary translocations, which sometimes do not involve Ig loci, are more complex, and are not mediated by errors in B cell specific DNA modification mechanisms. They involve other chromosomal partners, notably 8q24 (c-myc), and are associated with tumor progression. Consistent with MM being the malignant counterpart of a long-lived PC, oncogenes dysregulated by primary IgH translocations in MM do not appear to confer an anti-apoptotic effect, but instead increase proliferation and/or inhibit differentiation. The fact that so many different primary transforming events give rise to tumors with the same phenotype suggests that there is only a single fate available for the transformed cell.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ahmann GJ, Jalal SM, Juneau AL, Christensen ER, Hanson CA, Dewald GW, Greipp PR . 1998 Cancer Genet. Cytogenet. 101: 7–11
Avet-Loiseau H, Brigaudeau C, Morineau N, Talmant P, Lai JY, Daviet A, Li J-Y, Praloran V, Rapp M-J, Harousseau JL, Facon T, Bataille R . 1999a Genes Chrom. Cancer 24: 9–15
Avet-Loiseau H, Daviet A, Brigaudeau C, Callet-Bauchu E, Terre C, Lafage-Pochitaloff M, Desangles F, Ramond S, Talmant P, Bataille R . 2001 Blood 97: 822–825
Avet-Loiseau H, Facon T, Daviet A, Godon C, Rapp MJ, Harousseau JL, Grosbois B, Bataille R . 1999b Cancer Res. 59: 4546–4550
Avet-Loiseau H, Li JY, Facon T, Brigaudeau C, Morineau N, Maloisel F, Rapp MJ, Talmant P, Trimoreau F, Jaccard A, Harousseau JL, Bataille R . 1998 Cancer Res. 58: 5640–5645
Avet-Loiseau H, Li JY, Morineau N, Facon T, Brigaudeau C, Harousseau JL, Grosbois B, Bataille R . 1999c Blood 94: 2583–2589
Bakkus MH, Heirman C, Van Riet I, Van Camp B, Thielemans K . 1992 Blood 80: 2326–2335
Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM . 2000 Cancer Res. 60: 2140–2145
Bergsagel PL, Chesi MC, Nardini E, Brents LA, Kirby SL, Kuehl WM . 1996 Proc. Nal. Acad. Sci. USA 93: 13931–13936
Brezinschek HP, Foster SJ, Dorner T, Brezinschek RI, Lipsky PE . 1998 J. Immunol. 160: 4762–4767
Bulger M, Groudine M . 1999 Genes Dev 13: 2465–2477
Calasanz MJ, Cigudosa JC, Odero MD, Ferreira C, Ardanaz MT, Fraile A, Carrasco JL, Sole F, Cuesta B, Gullon A . 1997 Genes, Chrom. Cancer 18: 84–93
Chesi M, Bergsagel PL, Brents LA, Smith CM, Gerhard DS, Kuehl WM . 1996 Blood 88: 674–681
Chesi M, Bergsagel PL, Shonukan OO, Martelli ML, Brents LA, Chen T, Schrock E, Ried T, Kuehl WM . 1998a Blood 91: 4457–4463
Chesi M, Brents LA, Ely SA, Bais C, Robbiani DF, Mesri EA, Kuehl WM, Bergsagel PL . 2001 Blood 97: 729–736
Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM, Bergsagel PL . 1997 Nat. Genet 16: 260–264
Chesi M, Nardini E, Lim RSC, Smith KD, Kuehl WM, Bergsagel PL . 1998b Blood 92: 3025–3034
Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM . 1982 Proc. Natl. Acad. Sci. USA 79: 7824–7827
Dalla-Favera R, Gaidano G . 2001 Cancer: Principles and Practice of Oncology DeVita VTSH and Rosenberg SA. (eds) Lippincott Williams and Wilkins: Philadelphia pp. 2215–2235
Dewald GW, Kyle RA, Hicks GA, Greipp PR . 1985 Blood 66: 380–390
Difilippantonio MJ, Zhu J, Chen HT, Meffre E, Nussenzweig MC, Max EE, Ried T, Nussenzweig A . 2000 Nature 404: 510–514
Dillon N, Trimborn T, Strouboulis J, Fraser P, Grosveld F . 1997 Mol. Cell. 1: 131–139
Ferguson DO, Sekiguchi JM, Chang S, Frank KM, Gao Y, DePinho RA, Alt FW . 2000 Proc. Natl. Acad. Sci. USA 97: 6630–6633
Fonseca R, Witzig TE, Gertz MA, Kyle RA, Hoyer JD, Jalal SM, Greipp PR . 1998 Br. J. Haematol 101: 296–301
Gabrea A, Bergsagel PL, Chesi M, Shou Y, Kuehl WM . 1999 Molec. Cell. 3: 119–123
Goossens T, Klein U, Kuppers R . 1998 Proc. Natl. Acad. Sci. USA 95: 2463–2468
Hatzivassiliou G, Miller I, Takizawa J, Palanisamy N, Rao PH, Iida S, Tagawa S, Taniwaki M, Russo J, Neri A, Cattoretti G, Clynes R, Mendelsohn C, Chaganti RS, Dalla-Favera R . 2001 Immunity 14: 277–289
Ho IC, Hodge MR, Rooney JW, Glimcher LH . 1996 Cell 85: 973–983
Iida S, Rao PH, Butler M, Corradini P, Boccadoro M, Klein B, Chaganti RS, Dalla-Favera R . 1997 Nat. Genet 17: 226–230
Jager U, Bocskor S, Le T, Mitterbauer G, Bolz I, Chott A, Kneba M, Mannhalter C, Nadel B . 2000 Blood 95: 3520–3529
Janssen JW, Vaandrager JW, Heuser T, Jauch A, Kluin PM, Geelen E, Bergsagel PL, Kuehl WM, Drexler HG, Otsuki T, Bartram CR, Schuuring E . 2000 Blood 95: 2691–2698
Kakkis E, Riggs KJ, Gillespie W, Calame K . 1989 Nature 339: 718–721
Kovalchuk AL, Esa A, Coleman AE, Park SS, Reed T, Cremer CC, Janz S . 2001 Genes Chrom. Cancer 30: 283–290
Krummel KA, Roberts LR, Kawakami M, Glover TW, Smith DI . 2000 Genomics 69: 37–46
Kuppers R, Klein U, Hansmann ML, Rajewsky K . 1999 N. Engl. J. Med. 341: 1520–1529
Kyle RA, Rajkumar SV . 1999 Hematol. Oncol. Clin. North. Am. 13: 1181–1202
Lai JL, Zandecki M, Mary JY, Bernardi F, Izydorczyk V, Flactif M, Morel P, Jouet JP, Bauters F, Facon T . 1995 Blood 85: 2490–2497
MacLennan ICM . 1998 Myeloma: Biology and Management Malpas JS, Bergsagel DE, Kyle RA and Anderson KC. (eds). Oxford University Press: Oxford pp. 29–47
Malgeri U, Baldini L, Perfetti V, Fabris S, Vignarelli MC, Colombo G, Lotti V, Compasso S, Bogni S, Lombardi L, Maiolo AT, Neri A . 2000 Cancer Res. 60: 4058–4061
Malpas JS, Bergsagel DE, Kyle R, Anderson K . 1998 Multiple Myeloma: Biology and Management Oxford University Press: Oxford
Max EE . 1999 Fundamental Immunology Paul WE. (ed.) Lippincott-Raven: Philadelphia pp. 113–184
Mitelman F, Johansson B, Mertens F . 2001 http://egap.nci.mih.gov/chromosomes
Nakazawa N, Nishida K, Tamura A, Kobayashi M, Iwai T, Horiike S, Nishigaki H, Otsuki T, Tomiyama Y, Fujii H, Kashima K, Taniwaki M . 2000 Cancer Genet. Cytogenet 117: 89–96
Neri A, Barriga F, Knowles DM, Magrath IT, Dalla-Favera R . 1988 Proc. Natl. Acad. Sci. USA 85: 2748–2752
Nishida K, Tamura A, Nakazawa N, Ueda Y, Abe T, Matsuda F, Kashima K, Taniwaki M . 1997 Blood 90: 526–534
Papavasiliou FN, Schatz DG . 2000 Nature 408: 216–221
Pasqualucci L, Migliazza A, Fracchiolla N, William C, Neri A, Baldini L, Chaganti RS, Klein U, Kuppers R, Rajewsky K, Dalla-Favera R . 1998 Proc. Natl. Acad. Sci. USA 95: 11816–11821
Plowright EE, Li Z, Bergsagel PL, Chesi M, Barber D, Branch DR, Hawley RG, Stewart AK . 2000 Blood 95: 992–998
Pratt G, Fenton JA, Davies FE, Rawstron AC, Richards SJ, Collins JE, Owen RG, Jack AS, Smith GM, Morgan GJ . 2001 Br. J. Haematol 112: 388–391
Qian L, Gong J, Liu J, Broome JD, Koduru PR . 1999 Br. J. Haematol 106: 477–485
Rao PH, Cigudosa JC, Ning Y, Calasanz MJ, Iida S, Tagawa S, Michaeli J, Klein B, Dalla-Favera R, Jhanwar SC, Ried T, Chaganti RS . 1998 Blood 92: 1743–1748
Richelda R, Ronchetti D, Baldini L, Cro L, Viggiano L, Marzella R, Rocchi M, Otsuki T, Lombardi L, Maiolo AT, Neri A . 1997 Blood 90: 4062–4070
Ried K, Finnis M, Hobson L, Mangelsdorf M, Dayan S, Nancarrow JK, Woollatt E, Kremmidiotis G, Gardner A, Venter D, Baker E, Richards RI . 2000 Hum. Mol. Genet. 9: 1651–1663
Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK . 2000 SEER Cancer Statistics Review, 1973–1997 National Cancer Institute: Bethesda
Ronchetti D, Finelli P, Richelda R, Baldini L, Rocchi M, Viggiano L, Cuneo A, Bogni S, Fabris S, Lombardi L, Maiolo AT, Neri A . 1999 Blood 93: 1330–1337
Sahota SS, Leo R, Hamblin TJ, Stevenson FK . 1996 Blood 87: 746–755
Sawyer JR, Lukacs JL, Munshi N, Desikan KR, Singhal S, Mehta J, Siegel D, Shaughnessy J, Barlogie B . 1998 Blood 92: 4269–4278
Sawyer JR, Lukacs JL, Thomas EL, Swanson CM, Goosen LS, Sammartino G, JC G, Munshi NC, Tricot G, Shaughnessy JD, Barlogie B . 2000 Br. J. Haematol. 112: 1–9
Sawyer JR, Waldron JA, Jagannath S, Barlogie B . 1995 Cancer Genet. Cytogenet. 82: 41–49
Shaughnessy J, Gabrea A, Qi Y, Brents LA, Zhan F, Tian E, Sawyer J, Barlogie B, Bergsagel PL, Kuehl WM . 2001 Blood 98: 217–223
Shen-Ong GL, Keath EJ, Piccoli SP, Cole MD . 1982 Cell 31: 443–452
Shou Y, Martelli ML, Gabrea A, Qi Y, Brents LA, Roschke A, Dewald G, Kirsch IR, Bergsagel PL, Kuehl WM . 2000 Proc. Natl. Acad. Sci. USA 97: 228–233
Stec I, Wright TJ, van Ommen GJ, de Boer PA, van Haeringen A, Moorman AF, Altherr MR, den Dunnen JT . 1998 Hum. Mol. Genet. 7: 1071–1082
Vanasse GJ, Concannon P, Willerford DM . 1999 Blood 94: 3997–4010
Welzel N, Le T, Marculescu R, Mitterbauer G, Chott A, Pott C, Kneba M, Du MQ, Kusec R, Drach J, Raderer M, Mannhalter C, Lechner K, Nadel B, Jaeger U . 2001 Cancer Res. 61: 1629–1636
Willis TG, Jadayel DM, Coignet LJ, Abdul-Rauf M, Treleaven JG, Catovsky D, Dyer MJ . 1997 Blood 90: 2456–2464
Ye BH, Chaganti S, Chang CC, Niu H, Corradini P, Chaganti RS, Dalla-Favera R . 1995 EMBO J 14: 6209–6217
Yoshida S, Nakazawa N, Iida S, Hayami Y, Sato S, Wakita A, Shimizu S, Taniwaki M, Ueda R . 1999 Leukemia 13: 1812–1816
Zeidler R, Joos S, Delecluse HJ, Klobeck G, Vuillaume M, Lenoir GM, Bornkamm GW, Lipp M . 1994 Genes Chrom. Cancer 9: 282–287
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bergsagel, P., Kuehl, W. Chromosome translocations in multiple myeloma. Oncogene 20, 5611–5622 (2001). https://doi.org/10.1038/sj.onc.1204641
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204641
Keywords
This article is cited by
-
Evaluation of Genes and Molecular Pathways Involved in the Progression of Monoclonal Gammopathy of Undetermined Significance (MGUS) to Multiple Myeloma: A Systems Biology Approach
Molecular Biotechnology (2023)
-
The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma
Leukemia (2021)
-
Anti-bacterial and anti-viral nanchangmycin displays anti-myeloma activity by targeting Otub1 and c-Maf
Cell Death & Disease (2020)
-
Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells
Scientific Reports (2019)
-
Bromodomains: a new target class for drug development
Nature Reviews Drug Discovery (2019)